CN1443070A - 包含15－酮基－前列腺素或其衍生物的编程性细胞死亡抑制组合物 - Google Patents

包含15－酮基－前列腺素或其衍生物的编程性细胞死亡抑制组合物 Download PDF

Info

Publication number
CN1443070A
CN1443070A CN01809737A CN01809737A CN1443070A CN 1443070 A CN1443070 A CN 1443070A CN 01809737 A CN01809737 A CN 01809737A CN 01809737 A CN01809737 A CN 01809737A CN 1443070 A CN1443070 A CN 1443070A
Authority
CN
China
Prior art keywords
keto
prostaglandin compound
prostaglandin
compound
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN01809737A
Other languages
English (en)
Chinese (zh)
Inventor
上野隆司
真岛行彦
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sucampo GmbH
Original Assignee
Sucampo GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sucampo GmbH filed Critical Sucampo GmbH
Publication of CN1443070A publication Critical patent/CN1443070A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/558—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN01809737A 2000-03-24 2001-03-23 包含15－酮基－前列腺素或其衍生物的编程性细胞死亡抑制组合物 Pending CN1443070A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19175500P 2000-03-24 2000-03-24
US60/191,755 2000-03-24

Publications (1)

Publication Number Publication Date
CN1443070A true CN1443070A (zh) 2003-09-17

Family

ID=22706808

Family Applications (1)

Application Number Title Priority Date Filing Date
CN01809737A Pending CN1443070A (zh) 2000-03-24 2001-03-23 包含15－酮基－前列腺素或其衍生物的编程性细胞死亡抑制组合物

Country Status (13)

Country Link
US (1) US7129272B2 (enExample)
EP (1) EP1267882B1 (enExample)
JP (1) JP2003527430A (enExample)
KR (1) KR100788226B1 (enExample)
CN (1) CN1443070A (enExample)
AR (1) AR030275A1 (enExample)
AT (1) ATE428429T1 (enExample)
AU (2) AU2001239551B8 (enExample)
CA (1) CA2403086C (enExample)
DE (1) DE60138371D1 (enExample)
NZ (1) NZ521464A (enExample)
TW (1) TWI284535B (enExample)
WO (1) WO2001070233A2 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4786866B2 (ja) 2001-08-31 2011-10-05 スキャンポ・アーゲー クロライドチャンネルオープナーとしてのプロスタグランジンアナログ
CN1605336A (zh) * 2003-10-10 2005-04-13 中国医学科学院药物研究所 左旋丁基苯酞在制备预防和治疗脑梗塞的药物中的应用
JP5147404B2 (ja) * 2005-01-27 2013-02-20 スキャンポ・アーゲー 中枢神経系障害の処置のための方法および組成物
CN102293774A (zh) * 2005-03-31 2011-12-28 旭硝子株式会社 前列腺素F2α衍生物的应用
EP1870099A4 (en) 2005-04-13 2008-07-16 Ube Industries PROTECTION AGAINST RETINAL NERVOUS CELLS WITH INDAZOLE DERIVATIVE AS ACTIVE SUBSTANCE
EP1803809A3 (en) * 2005-08-12 2007-12-19 Abgenomics Corporation Modulation of peroxisome proliferator-activated receptors
US8871752B2 (en) 2008-02-19 2014-10-28 Sucampo Ag Method for modulating stem cell growth
WO2010027040A1 (ja) * 2008-09-04 2010-03-11 参天製薬株式会社 １５，１５－ジフルオロプロスタグランジンＦ2α誘導体を有効成分として含有する毛髪成長促進剤
US9084815B2 (en) * 2009-09-16 2015-07-21 Sucampo Ag Method for treating damage induced by an anti-tumor agent, treating mucositis and treating tumor
WO2014159679A1 (en) 2013-03-12 2014-10-02 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Methods for using lubiprostone to absorb fluid from the subretinal space

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5166174A (en) 1987-01-28 1992-11-24 K.K. Ueno Seiyaku Oyo Kenkyujo Prostaglandins E and anti-ulcers containing same
CA1322749C (en) 1987-01-28 1993-10-05 Ryuzo Ueno Prostaglandins of the d series, and tranquilizers and soporifics containing the same
US5221763A (en) 1987-04-30 1993-06-22 R-Tech Ueno, Ltd. Prostaglandins of the F series
GB2209939B (en) * 1987-09-18 1992-01-02 R Tech Ueno Ltd The use of 13,14-dihydro-15-keto-prostaglandins as ocular hypotensive agents
JPH0761944B2 (ja) * 1989-11-22 1995-07-05 株式会社アールテック・ウエノ 脳機能改善処置剤
CA2030345C (en) * 1989-11-22 1998-12-08 Ryuji Ueno Use of 15-keto-prostaglandin compound for improvement of encephalic function
TW249226B (enExample) 1990-04-04 1995-06-11 Aderk Ueno Kk
CA2150287C (en) 1994-06-03 2004-08-10 Ryuji Ueno Agent for treating hepato-biliary diseases
JP3625946B2 (ja) * 1995-03-10 2005-03-02 株式会社アールテック・ウエノ 視神経障害改善剤
JPH08277222A (ja) * 1995-04-05 1996-10-22 Green Cross Corp:The 神経疾患の予防治療剤
US6087395A (en) 1997-10-21 2000-07-11 Japan Science And Technology Corporation Isocarbacyclin derivatives as apoptosis inhibitors
JP3964060B2 (ja) * 1997-10-21 2007-08-22 独立行政法人科学技術振興機構 アポトーシス抑制剤
JP2000169394A (ja) * 1998-12-04 2000-06-20 Yoshitomi Pharmaceut Ind Ltd アポトーシス誘導剤

Also Published As

Publication number Publication date
CA2403086C (en) 2010-08-17
WO2001070233A3 (en) 2002-06-13
AU3955101A (en) 2001-10-03
AU2001239551B2 (en) 2005-07-21
TWI284535B (en) 2007-08-01
US7129272B2 (en) 2006-10-31
AU2001239551B8 (en) 2005-11-24
US20020025985A1 (en) 2002-02-28
JP2003527430A (ja) 2003-09-16
KR20020081474A (ko) 2002-10-26
EP1267882B1 (en) 2009-04-15
CA2403086A1 (en) 2001-09-27
DE60138371D1 (de) 2009-05-28
ATE428429T1 (de) 2009-05-15
NZ521464A (en) 2004-09-24
EP1267882A2 (en) 2003-01-02
AR030275A1 (es) 2003-08-20
KR100788226B1 (ko) 2007-12-26
WO2001070233A2 (en) 2001-09-27

Similar Documents

Publication Publication Date Title
US20100298424A1 (en) Method for treating abdominal discomfort
US6982283B2 (en) Method for treating drug-induced constipation
JP2008291033A (ja) １５−ケトプロスタグランジンを含む胆汁分泌促進剤組成物
JP5427029B2 (ja) 消化管の重炭酸分泌を促進するための方法および組成物
US8114911B2 (en) Prostaglandin compounds for the treatment of obesity
AU2001239551B2 (en) Apoptosis inhibiting composition comprising a 15-keto-prostaglandin or derivative thereof
AU2001239551A1 (en) Apoptosis inhibiting composition comprising a 15-keto-prostaglandin or derivative thereof
KR20120018158A (ko) 황반변성을 치료하기 위한 방법 및 조성물
US20030060511A1 (en) Method for treatment of ocular hypertension and glaucoma
US20040225014A1 (en) Method for treating ocular hypertension and glaucoma
JPWO1999018968A1 (ja) 門脈圧亢進抑制剤
KR20120031954A (ko) 클라우딘 매개 기능을 조정하고 피부 장애를 치료하는데 사용하기 위한 프로스타글란딘 유도체를 포함하는 제약 조성물
US20160120840A1 (en) Method and composition for treating nonerosive reflux disease
AU2002326160A1 (en) Method and composition for treatment of ocular hypertension and glaucoma

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication